Correlation of SARS-CoV-2 IgG/IgM Levels to COVID-19 Severity in Convalescent Plasma Donor Candidates
DOI:
https://doi.org/10.24293/ijcpml.v30i1.2058Keywords:
IgM/IgG, COVID-19 severity, convalescent plasmaAbstract
Coronavirus Disease-19 (COVID-19) is an infectious disease caused by Sars-CoV-2. The clinical manifestations of COVID-19 vary from asymptomatic, mild symptoms to severe symptoms. Plasma of people recovering from COVID-19 infection will likely contain specific polyclonal antibodies. These antibodies can provide passive immunity to the recipient. This study aimed to analyze the correlation of SARS-CoV-2 IgG/IgM levels to COVID-19 severity and length of negative conversion in COVID-19 patients as convalescent plasma donor candidates. The retrospective research used this study with data collected from May to December 2020. The study sample of 30 patients was taken from the medical record with a population that met the inclusion criteria. IgG/IgM levels were measured using AFIAS-6 Immunoanalyzer. The Shapiro-Wilk and Spearman rho non-parametric correlation tests were used for data analysis. The statistical test results with p-value <0.05 were reported as significant. There was no significant correlation between IgM levels and COVID-19 severity, with a p-value of 0.763 (p>0.05) and length of negative conversion with a p-value of 0.998 (p>0.05). There was a significant correlation between IgG levels and COVID-19 severity with a p-value of 0.014 (p<0.05) and length of negative conversion with a p-value of 0.004 (p<0.05). IgM/IgG levels affect the severity of the disease. IgM levels increase at the beginning of infection and decrease as the disease progresses, and IgG levels will increase slowly. IgM levels cannot be used to detect previous SARS CoV-2 infection, whereas IgG levels affect the length of negative conversion. There was a significant correlation between IgG and the severity of COVID-19 with a correlation strength of R=0.444 (weak correlation) and with a length of negative conversion with a relationship strength of R=0.509 (moderate correlation). SARS CoV-2 IgG levels of convalescent plasma donor candidates correlated to the severity and length of negative conversion.
Downloads
References
da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wiener Klinische Wochenschrift, 2021; 133: 377-382.
Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell [Internet]. 2021; 184(2): 476-488.e11. Available from: https://doi.org/10.1016/j.cell.2020.12.015 (accessed August 04, 2022).
Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura-Ikeda M, et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol, 2021; 93(5): 3211–8.
Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front Microbiol, 2020; 11: 1–8.
Okba NMA, Müller MA, Li W, Wang C, Geurtsvankessel CH, et al. Severe acute respiratory syndrome Coronavirus 2-specific antibody responses in Coronavirus disease patients. Emerg Infect Dis, 2020; 26(7): 1478–88.
Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, et al. A systematic review of antibody-mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat Commun, 2020; 11(1): 1–16.
Wang Y, Zhang L, Sang L, Ye F, Ruan S, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest, 2020; 130(10): 5235–44.
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020; 130(6): 2757 2765.
Sun B, Feng Y, Mo X, Zheng P, Wang Q, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes 1. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wiener Klinische Wochenschrift, 2021; 133: 377-382.
Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell [Internet]. 2021; 184(2): 476-488.e11. Available from: https://doi.org/10.1016/j.cell.2020.12.015 (accessed August 04, 2022).
Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura-Ikeda M, et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol, 2021; 93(5): 3211–8.
Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front Microbiol, 2020; 11: 1–8.
Okba NMA, Müller MA, Li W, Wang C, Geurtsvankessel CH, et al. Severe acute respiratory syndrome Coronavirus 2-specific antibody responses in Coronavirus disease patients. Emerg Infect Dis, 2020; 26(7): 1478–88.
Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, et al. A systematic review of antibody-mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat Commun, 2020; 11(1): 1–16.
Wang Y, Zhang L, Sang L, Ye F, Ruan S, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest, 2020; 130(10): 5235–44.
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020; 130(6): 2757 2765.
Sun B, Feng Y, Mo X, Zheng P, Wang Q, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect, 2020; 9(1): 940–8.
Chen Y, Klein, SL, Garibaldi BT, Li H, Wu C, et al. Aging in COVID-19: Vulnerability, immunity, and intervention. Aging Research Reviews, 2021; 65: 101205.
Fenty F, Putra IMAA. Antibody responses to SARS-COV-2 of COVID-19 patients based on the disease severity. Indonesian Journal of Clinical Pathology and Medical Laboratory, 2023; 29(1): 43 – 46.
Ozturk T, Howell J, Benameur K, Ramonell R, Cashman K, et al. Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection. medRxiv, 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273267/ (accessed August 03, 2022).
Zhenjiang Bai, Qing Li, Qinghui Chen, Changmin Niu, Yu Wei, et al. Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China. Journal of Intensive Medicine. ELSEVIER, 2022; 2(1): 32-38.
Jin Y, Wang M, Zuo Z, Fan C, Ye F, et al. Diagnostic value and dynamic variance of serum antibody in Coronavirus disease 2019. Int J Infect Dis, 2020; 94: 49-52.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
